Loading stock data…
Aytu BioPharma (AYTU)
$2.15-0.04 (-1.83%)
Market ClosedLast close Jun 30
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aytu BioPharma, Inc. in the Healthcare sector is trading at $2.15 with a market capitalization of $22M. Wall Street consensus targets $9.50 (3 analysts), implying a +341.9% move over the next 12 months. The stock is currently 30% below its 52-week high of $3.07, remaining 9.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +341.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.41M↓ | $15.16M↑ | $13.89M↓ | $15.13M↓ | $18.45M |
| Gross Profit | $7.60M↓ | $9.62M↑ | $9.19M↓ | $10.25M↓ | $12.81M |
| Operating Income | -$4.06M↓ | -$1.97M↓ | -$1.50M↓ | $640,000↓ | $2.42M |
| Net Income | -$5.62M↑ | -$10.58M↓ | $1.97M↑ | -$19.82M↓ | $3.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-96.90%
Volume
Today's trading volume
69,923
Recent News
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aytu BioPharma, Inc.'s Q3 2026 earnings call
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...
Aytu BioPharma Inc (AYTU) reports robust initial traction for Exua despite a decline in net revenue and profit margins.
Aytu (AYTU) Q3 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal 26 third quarter operational and financial results. Joining us on today's call is Aytu's chief executive officer, Joshua R. Disbrow and Ryan J. Selhorn, the company's chief financial officer.
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53861 Summary Aytu Biopharma Inc reported a net revenue of $12.4 million for Q3 2026, down 33% year over year, impacted by a strategic shi
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?